- The report contains detailed information about Dainippon Sumitomo Pharma Co., Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Dainippon Sumitomo Pharma Co., Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Dainippon Sumitomo Pharma Co., Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Dainippon Sumitomo Pharma Co., Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Dainippon Sumitomo Pharma Co., Ltd. business.
About Dainippon Sumitomo Pharma Co., Ltd.
Dainippon Pharmaceutical Co., Ltd. engages in the manufacture and marketing of Pharmaceuticals, Diagnostics, Veterinary products, Feeds and Feed additives, Food additives, and Chemicals.
The companys subsidiaries include: Gokyo Trading Co., Ltd.; Nichiei Sangyo Co., Ltd.; Marupi Drug Co., Ltd.; and Marupi Butsuryu Service Co., Ltd.
The company, through its pharmaceuticals business, focuses on ethical pharmaceuticals in addition to offering over-the counter drugs and diagnostics.
The company's pharmaceutical products include KLARICID (clarithromycin), a Macrolide antibiotic; GASMOTIN (mosapride citrate), a Gastroprokinetic; ENSURE LIQUID, an Enteral nutrition; EBASTEL (ebastine), an Antiallergic; PRORENAL, a Vasodilator; SYNAGIS (palivizumab), a Monoclonal antibody; EXCEGRAN (zonisamide), an Antiepileptic, GLIMICRON (gliclazide), an Oral hypoglycemic; SEVOFRANE (sevoflurane), an Anesthetic; LOPEMIN (loperamide hydrochloride), an Antidiarrheal; QVARTM (beclomethasone dipropionate), a Bronchial asthma, SERENACE (haloperidol) a Psychotropic drug.
The gastroprokinetic GASMOTIN (mosapride citrate) was independently developed by Dainippon Pharmaceutical. The selective serotonin 5-HT4 receptor agonist, GASMOTIN promotes gastrointestinal motility, there is a reduced likelihood of extrapyramidal adverse reactions or prolonged QT intervals. PRORENAL (limaprost alfadex) is an orally administered prostaglandin agent for the improvement of peripheral circulation, which was jointly developed with Ono Pharmaceutical Co., Ltd. QVARTM (beclomethasone dipropionate) is an inhaled steroid asthma treatment was launched in 2002. Licensed from 3M Pharmaceuticals, QVARTM is an MDI that uses an ozonesafe non-CFC propellant.
The antiepileptic agent EXCEGRAN (zonisamide), developed in-house, is valued by specialists for its activity and superior efficacy in refractory cases. EBASTEL (ebastine), an antiallergy drug licensed from Almirall Prodesfarma, S.A. KLARICID (clarithromycin) is an macrolide antibiotic the enteral nutrition product ENSURE LIQUID, and the humanized monoclonal antibody for prevention of respiratory syncytial virus (RSV) infection SYNAGIS (palivizumab), which were developed by Dainabot Co., Ltd.
Dainippon Pharmaceutical also markets other products internationally, from ethical pharmaceuticals, such as quinolone antibacterials, a cardiovascular agent, an intravenous iron preparation and an antiallergic agent to animal health products, food additives and diagnostic products. Overseas bases consist of Dainippon Pharmaceutical U.S.A. Corporation, as well as offices in Beijing and London, which provide support for overseas product development, facilitate communication with licensees, and collect information on local markets. A wholly owned subsidiary in Taiwan, Taiwan Dainippon Pharmaceutical Co., Ltd. is involved in product development and marketing.
Dainippon Pharmaceutical engages in the development and marketing of vitro diagnostic products, including kits that diagnose illness by measuring or detecting biochemical markers and kits that measure the blood concentration of given drugs. The kits are used in hospitals and clinical assay laboratories throughout Japan.
The companys diagnostic product RAPICHECK H-FABP is a point-of care in vitro diagnostic. Developed jointly with Wakunaga Pharmaceutical Co., Ltd., RAPICHECK is a reagent that uses immunochromatography to detect human heart fatty acid-binding protein (H-FABP) in whole blood within 15 minutes. Dainippon Pharmaceutical also markets MARKIT-M H-FABP, which measures H-FABP concentration using the enzyme-linked immunosorbent assay (ELISA) method.
Other products in the MARKIT series include MARKIT-M PA, which measures prostate-specific antigen (PSA) in blood and is used in the diagnosis of prostate cancer, and MARKIT-M PSA-ACT, which measures the new diagnostic prostate marker PSA -Eø1 -antichymotrypsin complex (PSA-ACT). Hyperlipemia diagnostics include MARKIT- M LPL, which measures lipoprotein lipase (LPL) in post-heparin plasma, and a kit that measures hepatic triglyceride lipase (HTGL) for
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. DAINIPPON SUMITOMO PHARMA CO., LTD. COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. DAINIPPON SUMITOMO PHARMA CO., LTD. BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. DAINIPPON SUMITOMO PHARMA CO., LTD. SWOT ANALYSIS
4. DAINIPPON SUMITOMO PHARMA CO., LTD. FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. DAINIPPON SUMITOMO PHARMA CO., LTD. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Dainippon Sumitomo Pharma Co., Ltd. Direct Competitors
5.2. Comparison of Dainippon Sumitomo Pharma Co., Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Dainippon Sumitomo Pharma Co., Ltd. and Direct Competitors Stock Charts
5.4. Dainippon Sumitomo Pharma Co., Ltd. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Dainippon Sumitomo Pharma Co., Ltd. Industry Position Analysis
6. DAINIPPON SUMITOMO PHARMA CO., LTD. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. DAINIPPON SUMITOMO PHARMA CO., LTD. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. DAINIPPON SUMITOMO PHARMA CO., LTD. ENHANCED SWOT ANALYSIS2
9. JAPAN PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. DAINIPPON SUMITOMO PHARMA CO., LTD. IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. DAINIPPON SUMITOMO PHARMA CO., LTD. PORTER FIVE FORCES ANALYSIS2
12. DAINIPPON SUMITOMO PHARMA CO., LTD. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Dainippon Sumitomo Pharma Co., Ltd. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Dainippon Sumitomo Pharma Co., Ltd. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Dainippon Sumitomo Pharma Co., Ltd. Major Shareholders
Dainippon Sumitomo Pharma Co., Ltd. History
Dainippon Sumitomo Pharma Co., Ltd. Products
Revenues by Segment
Revenues by Region
Dainippon Sumitomo Pharma Co., Ltd. Offices and Representations
Dainippon Sumitomo Pharma Co., Ltd. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Dainippon Sumitomo Pharma Co., Ltd. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Dainippon Sumitomo Pharma Co., Ltd. Capital Market Snapshot
Dainippon Sumitomo Pharma Co., Ltd. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Dainippon Sumitomo Pharma Co., Ltd. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Dainippon Sumitomo Pharma Co., Ltd. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Dainippon Sumitomo Pharma Co., Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Dainippon Sumitomo Pharma Co., Ltd. 1-year Stock Charts
Dainippon Sumitomo Pharma Co., Ltd. 5-year Stock Charts
Dainippon Sumitomo Pharma Co., Ltd. vs. Main Indexes 1-year Stock Chart
Dainippon Sumitomo Pharma Co., Ltd. vs. Direct Competitors 1-year Stock Charts
Dainippon Sumitomo Pharma Co., Ltd. Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?